For immediate release
22 November 2022
Xtract Resources Plc
("Xtract" or the "Company")
Application update
The Board of Xtract announces that application to trading on AIM on or around 29 November 2022 ("Admission") has now been made for 5,362,229 new Ordinary Shares issued at a price of 3.23p per Ordinary Share, issued in settlement of accrued outstanding remuneration in relation to 2021, due to certain Directors and employees of the Company ("Settlement Shares") and the issue of 619,195 new Ordinary Shares ("Creditor Settlement Shares") issued at a price of 3.23p per Ordinary share, in aggregate amounting to 5,981,424 new Ordinary Shares ("New Shares"), as announced on 4 November 2022. The New Shares will rank pari passu in all respects with the Company's existing issued ordinary shares.
Total Voting Rights
On Admission, the Company's issued share capital consists of 856,375,115 ordinary shares of 0.02p each with voting rights ("Ordinary Shares"). The Company does not hold any Ordinary Shares in Treasury. Therefore, the total number of Ordinary Shares in the Company with voting rights is 856,375,115. The above figure of 856,375,115 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.
A copy of this announcement: www.xtractresources.com
Enquiries:
| Xtract Resources Plc | Colin Bird, Executive Chairman
| +44 (0)20 3416 6471 |
| Beaumont Cornish Limited Nominated Adviser and Joint Broker | Roland Cornish Michael Cornish Felicity Geidt | +44 (0)207628 3369 |
|
Novum Securities Limited Joint Broker |
Jon Bellis Colin Rowbury |
+44 (0)207 399 9427 www.novumsecurities.com |
ENDS
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.